Adicet Bio Inc ACET:NASDAQ

Last Price$14.36NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/27/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$13.00 (1)
Ask (Size)$15.00 (10)
Day Low / HighN/A - N/A
Volume30.00

Adicet Bio Says FDA Grants Fast Track Designation for ADI-001 for Non-Hodgkin's Lymphoma

7:52AM ET 4/19/2022 MT Newswires
Adicet Bio (ACET) said Tuesday the US Food and Drug Administration has granted fast track designation to ADI-001, a CD20-targeted experimental medicine for the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma, a type of cancer.

ADI-001 is currently being evaluated in an ongoing early-stage dose escalation trial to determine its safety and tolerability.

The clinical-stage biotechnology company said it expects to report additional data from the early-stage trial of ADI-001 in the first half of 2022.

Shares rose 3.8% in premarket trading on Tuesday.

Price: 16.5, Change: +0.6, Percent Change: +3.77